Improving Bone Health Among Rheumatoid Arthritis (RA) Patients on Chronic Glucocorticoids

Improving Bone Health Among RA Patients on Chronic Glucocorticoids

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01378689

Enrollment

4659

Registered

2011-06-22

Start date

2010-09-30

Completion date

2012-12-31

Last updated

2013-01-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adverse Effect of Glucocorticoids and Synthetic Analogues, Osteoporosis, Rheumatoid Arthritis

Brief summary

This quality improvement project is aimed at improving health care by identifying low cost strategies to get Rheumatoid Arthritis (RA) patients to more effectively communicate with their physicians about osteoporosis prevention and treatment (improving doctor-patient communication). The investigators will implement a direct to patient intervention to the population of interest (patients on chronic glucocorticoids) via story-telling, using an Internet based video. The target audience is people on chronic glucocorticoids not already receiving bones-specific osteoporosis medications to determine differences in post-intervention rates of osteoporosis care, and the rates of prescription anti-osteoporosis therapies.

Interventions

OTHERStorytelling online video

patients with a history of chronic glucocorticoids use tell their experiences of side effects resulting from chronic use and provide advice on ways to prevent side effects

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

* Greater than or equal to 5 milligrams of prednisone or glucocorticoid dose equivalent for greater than or equal to 90 days within the previous 12 months * Medco member for entire study period * Refill steroid prescription online

Exclusion criteria

* anti-osteoporosis medication in previous 12 months

Design outcomes

Primary

Measure	Time frame	Description
Number of participants receiving Anti-osteoporosis Treatment	within 3 - 12 months of exposure to video	Includes bisphosphonates, PTH, SERM, Calcitonin

Secondary

Measure	Time frame	Description
Calcium and Vitamin D use	within 3 - 12 months of exposure to video	Are participants taking calcium and vitamin d supplements
Patient-Physician Communication	within 3 - 12 months of exposure to video	Did viewing the video increase patient-physician communication

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026